Ijioma Nkechinyere, Robinson Jennifer G
University of Iowa, Iowa City, IA, USA.
Expert Rev Cardiovasc Ther. 2011 Feb;9(2):131-45. doi: 10.1586/erc.10.179.
Ezetimibe/simvastatin is a combination of a statin and a cholesterol absorption inhibitor. This article reviews current information on the pharmacology, clinical efficacy and safety of ezetimibe/simvastatin combination therapy as a lipid-lowering pharmacologic option. Focus is on the LDL cholesterol-lowering efficacy of ezetimibe/simvastatin. PubMed was searched for english-language articles from January 2005 to 14 April 2010 using the keywords 'ezetimibe and simvastatin' and 'hyperlipidemia'. Reviewers screened all records and only English language papers and human clinical studies were included in the review. References of these papers were reviewed for relevant articles, and retrospective studies were excluded. Limitations include the exclusion of non-English publications, the use of only one data source (PubMed), and the fact that most studies were of short duration and several studies were of low quality (nonrandomized trials or meta-analyses). Ezetimibe and simvastatin has proven to be a well-tolerated, effective lipid-lowering drug combination. It is effective in reducing LDL-cholesterol and triglycerides, and increasing HDL-cholesterol. It also decreases C-reactive protein and exhibits some pleiotropic effects in a variety of patient populations. More data are needed to evaluate its effect on cardiovascular events/outcomes.
依折麦布/辛伐他汀是一种他汀类药物与胆固醇吸收抑制剂的复方制剂。本文综述了依折麦布/辛伐他汀联合治疗作为一种降脂药物选择的药理学、临床疗效及安全性方面的现有信息。重点在于依折麦布/辛伐他汀降低低密度脂蛋白胆固醇的疗效。利用关键词“依折麦布和辛伐他汀”以及“高脂血症”在PubMed数据库中检索2005年1月至2010年4月14日期间的英文文章。综述作者筛选了所有记录，仅纳入英文论文及人体临床研究。对这些论文的参考文献进行检索以查找相关文章，并排除回顾性研究。局限性包括排除了非英文出版物、仅使用了一个数据源（PubMed），以及大多数研究持续时间较短且有几项研究质量较低（非随机试验或荟萃分析）。依折麦布和辛伐他汀已被证明是一种耐受性良好、有效的降脂药物组合。它在降低低密度脂蛋白胆固醇和甘油三酯以及升高高密度脂蛋白胆固醇方面有效。它还能降低C反应蛋白，并在多种患者群体中呈现出一些多效性作用。需要更多数据来评估其对心血管事件/结局的影响。
